Juvenile Arthritis News

The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.

Emotional distress may trigger flares of periodic fever, aphthous stomatitis, pharyngitis and adenitis, or PFAPA syndrome, according to data published in Pediatric Rheumatology.

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

ORLANDO — As many as one-half of children with juvenile idiopathic arthritis enter adult care with increased disease activity, according to a speaker at the 2022 Rheumatology Nurses Society Conference.

The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.

When a tetanus toxoid vaccination is indicated, pediatric patients treated with B-cell depleting therapy in the past 6 months should receive passive immunization, according to updated EULAR vaccine recommendations.

The FDA has approved GlaxoSmithKline’s belimumab for the treatment of children with active lupus nephritis who are also receiving standard therapy, according to a company press release.

The risks for unresponsiveness to intravenous immunoglobulin and the development of coronary artery abnormalities differ between infants and older patients with Kawasaki disease, according to data published in JAMA Network Open.

More than 75% of patients with juvenile idiopathic arthritis experience pain that has interfered with their ability to sleep, pay attention and run or walk short distances, according to an Arthritis Foundation report.

Federal law prohibits pharmacies from refusing to fill prescriptions that may end a pregnancy to patients who are able to become pregnant, according to a newly released HHS guidance.